Doxorubicin is under clinical development by InnoMedica and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Doxorubicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Doxorubicin overview
Doxorubicin (TLD-1, Talidox) is under development for the treatment of soft tissue sarcoma. The drug candidate is administered intravenously as a liposomal formulation solution. It is developed based on liposomal targeting technology. The technology involves encapsulation of the drug candidate in a liposome with sugar chain, sialyl Lewis X attached to the liposome surface for targeting.
It was also under development for the treatment of advanced solid tumors such as ovarian cancer, breast cancer as a third line therapy.
InnoMedica overview
InnoMedica discovers and develops therapeutics for the treatment of cancer. The company develops drugs using its proprietary drug delivery technology, Talidox, based on the transport and release of active pharmaceutical agent, locally, at the target area. Its pipeline portfolio includes targeted liposomal doxorubicin TLD-1/Talidox for the treatment of advanced metastatic tumors. The company’s pipeline portfolio also includes other candidates for the therapeutic areas of autoimmune diseases such as multiple sclerosis, arteriosclerosis and chronic inflammatory diseases. It operates through a office and production facility in Bern and Marly located in Switzerland, respectively. InnoMedica is headquartered in Zug, Switzerland.
For a complete picture of Doxorubicin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
